Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viatris
Pharma
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Three Chinese obesity assets are featured in Verdiva's $410 million debut. Experts analyzed the buyout prospects of Legend and BeiGene. Plus more.
Angus Liu
Jan 10, 2025 9:00am
FDA warning letter reveals production errors at Viatris plant
Jan 6, 2025 4:20pm
Roche-Innovent, AstraZeneca, Viatris and more—Fierce Pharma Asia
Jan 3, 2025 8:37am
Viatris says India plant hit with FDA warning letter, import ban
Dec 23, 2024 10:50am
FDA expert panel spurns Lexicon's approval bid in type 1 diabetes
Nov 1, 2024 11:24am
Viatris lays out $25M to tackle marketing of Lexicon's Inpefa
Oct 17, 2024 10:17am
